Is it possible to stop nucleos(t)ide analogue treatment in chronic hepatitis B patients?

Existing Reviews

Please note, new claims can take a short while to show up.

No claims yet.

Annotation Summary

Term Occurence Count Dictionary
hepatitis C 1 infectiousdiseases
infectious disease 1 infectiousdiseases
lamivudine 1 infectiousdiseasesdrugs
tenofovir 3 infectiousdiseasesdrugs
hepatitis B 12 infectiousdiseases

Graph of close proximity drug and disease terms (within 200 characters).

Note: If this graph is empty, then there are no terms that meet the proximity constraint.

Review

Having read the paper, please pick a pair of statements from the paper to indicate that a drug and disease are related.

Select Drug Character Offset Drug Term Instance
lamivudine 5111 profile[[7]-[9]]. The currently approved NAs for CHB treatment in the United States and Europe include lamivudine (LMV), telbivudine (TBV), adefovir dipivoxil (ADV), tenofovir (disoproxil fumarate, TDF; alafenamide,
tenofovir 5174 the United States and Europe include lamivudine (LMV), telbivudine (TBV), adefovir dipivoxil (ADV), tenofovir (disoproxil fumarate, TDF; alafenamide, TAF) and entecavir (ETV). The NA mechanism of action comprises
tenofovir 17698 and bone toxicity, which are associated with TDF, perhaps the most widely used drug. However, the new tenofovir formulation TAF seems to have a better safety profile regarding these points. Other side effects appear
tenofovir 18041 neurologic toxicity.NAs have a relatively benign safety profile for pregnancy, with telbivudine and tenofovir being the most favourable ones, rated B category by the Federal Drug Administration. On the other hand,
Select Disease Character Offset Disease Term Instance
hepatitis B 107 World Journal of GastroenterologyIs it possible to stop nucleos(t)ide analogue treatment in chronic hepatitis B patients?Elia Moreno-CuberoRobert T Sánchez del ArcoInternal Medicine Service, Guadalajara University
hepatitis B 668 Spain. juan.larrubia@uah.esPublication date (ppub): 5/2018Publication date (epub): 5/2018AbstractChronic hepatitis B (CHB) remains a challenging global health problem, with nearly one million related deaths per year.
hepatitis B 889 Nucleos(t)ide analogue (NA) treatment suppresses viral replication but does not provide complete cure of the hepatitis B virus (HBV) infection. The accepted endpoint for therapy is the loss of hepatitis B surface antigen
hepatitis B 973 complete cure of the hepatitis B virus (HBV) infection. The accepted endpoint for therapy is the loss of hepatitis B surface antigen (HBsAg), but this is hardly ever achieved. Therefore, indefinite treatment is usually
hepatitis B 2255 discontinuation in both groups.Core tip: Nucleos(t)ide analogue (NA) treatment efficiently suppress hepatitis B virus replication. However, hepatitis B surface antigen loss, the optimal endpoint of NA therapy, is
hepatitis B 2295 Nucleos(t)ide analogue (NA) treatment efficiently suppress hepatitis B virus replication. However, hepatitis B surface antigen loss, the optimal endpoint of NA therapy, is rarely achieved. Thus, a major unmet need
hepatitis B 2439 optimal endpoint of NA therapy, is rarely achieved. Thus, a major unmet need in the management of chronic hepatitis B is the definition of earlier and safe treatment stopping points. There is growing clinical evidence
hepatitis B 2987 immunity.INTRODUCTIONAccording to recent data from the World Health Organization, about 257 million people suffer from chronic hepatitis B (CHB) worldwide. Hepatitis B virus (HBV) infection remains a major global health concern, as the disease
hepatitis B 5779 cure” is not a realistic endpoint of NAs to date. “Functional cure”, understood as HBV DNA and hepatitis B surface antigen (HBsAg) seroclearance with or without seroconversion, constitutes a more plausible goal.
hepatitis B 6028 a small proportion of the treated patients. Lifelong NA therapy is usually necessary, especially in hepatitis B e antigen-negative [HBeAg(-)] cases[[7],[12],[13]].Since indefinite treatment is mandatory, development
hepatitis B 14122 after liver failure have been reported.Table 2NA treatment cessation recommendations in the current hepatitis B virus guidelinesSocietyHBeAg(+)HBeAg(-)CirrhosisEASL (2017)[[9]]HBsAg clearance (safest) HBeAg seroconversion
hepatitis B 24526 virus persists despite high levels of HBV-specific antibodies[[62]] due to antigen overload, and only hepatitis B surface antibody is associated with disease resolution.Primed HBV-specific CD4 T cells are crucial to
hepatitis C 6760 parts of its life cycle, and follows practical successes observed in other infectious diseases, like hepatitis C virus and human immunodeficiency virus. Potential objectives regarding this approach include viral targeting
infectious disease 6734 attacking the virus in different parts of its life cycle, and follows practical successes observed in other infectious disease s, like hepatitis C virus and human immunodeficiency virus. Potential objectives regarding this approach

You must be authorized to submit a review.